Hims & Hers Health's (HIMS) Neutral Rating Reiterated at JPMorgan Chase & Co.

Key Points

• JPMorgan reiterated its “neutral” rating on Hims & Hers Health and maintained a $32 price target, implying approximately 16.27% upside from the reported share price.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $32.43; 12 analysts rate the stock Hold, compared with three Buys and one Sell.
• Hims & Hers reported quarterly revenue of $753.21 million, beating estimates and rising 38.2% year over year, but its adjusted loss of $0.37 per share significantly missed expectations of a $0.05 loss.

Hims & Hers Health (NYSE:HIMS - Get Free Report)'s stock had its "neutral" rating reiterated by analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday, Benzinga reports. They currently have a $32.00 price target on the stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 16.27% from the stock's current price.

Other research analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a report on Tuesday, August 11th. Truist Financial raised their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a research note on Monday, August 24th. Bank of America increased their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Barclays lowered their price target on Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a research note on Friday, August 21st. Finally, Wall Street Zen upgraded Hims & Hers Health from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $32.43.

Hims & Hers Health Trading Down 1.4%

Shares of HIMS stock opened at $27.52 on Friday. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a 50-day simple moving average of $31.05 and a 200 day simple moving average of $27.16. The stock has a market capitalization of $6.42 billion, a P/E ratio of -43.69 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period last year, the firm earned $0.17 earnings per share. The firm's revenue for the quarter was up 38.2% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health will post -0.1 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 16,773 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider directly owned 48,961 shares in the company, valued at approximately $1,363,563.85. This trade represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 190,227 shares of company stock valued at $6,133,613. 11.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently bought and sold shares of HIMS. Versant Capital Management Inc boosted its position in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company's stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after buying an additional 319 shares during the period. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the 3rd quarter worth approximately $28,000. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health in the first quarter valued at about $30,000. Finally, Greenline Wealth Management LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $36,000. Institutional investors own 63.52% of the company's stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Multiple law firms announced or promoted the same federal securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased HIMS securities from August 4, 2025, through July 29, 2026, with a lead-plaintiff deadline generally listed as November 2, 2026. The repeated announcements increase visibility around the litigation but do not represent separate lawsuits or a finding of wrongdoing. Kaplan Fox class-action announcement
• Negative Sentiment: The core concern is the Federal Trade Commission’s complaint, which reportedly alleges serious business misconduct and deceptive or unlawful privacy practices. The shareholder suit claims Hims & Hers and its executives made materially false or misleading statements or omitted important information, potentially creating legal costs, regulatory risk, reputational damage and uncertainty about future operations. The allegations have not been proven in court. HIMS securities class-action report
• Negative Sentiment: The litigation adds to existing investor concerns following Hims & Hers’ latest earnings report, where revenue exceeded estimates but the company posted a much larger-than-expected loss. A Zacks review said the stock had declined 7.7% since that report, underscoring elevated volatility and sensitivity to execution and regulatory developments. Zacks HIMS earnings-performance review

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.